Objective. To identify prognostic factors influencing the outcome of infertility treatment using intrauterine insemination with donor semen (IUI-D). Design. Retrospective study of all patients undergoing IUI-D between August 1st, 1990 and July 31st, 1998. Setting. University-affiliated infertility clinic. Patients. Three hundred and five couples undergoing 1131 IUI-D treatment cycles. Main outcome measures. Type of hormonal treatment, number of follicles, length of follicular phase, endometrial pattern, female age, infertility diagnosis and semen quality related to clinical pregnancy rate, cumulative birth rate and multiple gestations. Results. Throughout the nine year period the overall clinical pregnancy rate per cycle was 22.3%, with an increase from 12.9% in 1990 to 34.6% in 1998. The multiple birth rate was 20.6%. The birth rate per couple was 61.1% after a mean of 3.2 treatment cycles. The pregnancy rate was highest in the first treatment cycle and the cumulative birth rate rose only slightly after the sixth treatment cycle. The following parameters were positively and significantly correlated to a successful outcome of IUI-D: i) the first treatment cycle -compared to the following up to six treatment cycles; ii) number of mature follicles -more than one -at the time of insemination, however, with an unacceptable high rate of multiple pregnancies when more than 3 mature follicles were present; iii) time of insemination after the 12th day in the cycle; iv) insemination after ovulation has occurred and; v) female age under 30 years. Conclusions. IUI-D is a simple and inexpensive treatment giving acceptable pregnancy rates for up to six treatment cycles if at least 2 mature follicles have developed at the time of insemination, which implies that hormonal ovarian stimulation and induction of ovulation is used, and ovulation has occurred at the time of insemination, which ought to take place after cycle day (cd) 12 with at least two million motile spermatozoa.
Intrauterine insemination with donor semen (IUI-D) is a common treatment for couples with severe male-factor infertility. In Denmark it is statutory to use cryopreserved semen, quarantined for a Abbreviation: IUI-D: intrauterine insemination with donor semen.
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minimum of 6 months for donor insemination in order to avoid transmission of infectious diseases (1) . However, cryopreservation reduces the percentage of motile sperms after thawing and higher pregnancy rates are achieved using fresh semen (2) . Advances in insemination techniques, sperm preparations and timing of ovulation have enabled better results (3) . Several studies have shown that IUI-D outperforms intracervical or vaginal insemination (3) .
IUI-D involves the deposition of purified motile spermatozoa directly into the uterine cavity. To achieve fertilization and pregnancy, the insemination has to be synchronized with ovulation, either in a natural cycle or in a cycle with ovarian stimulation. Previous reports have demonstrated increased cycle fecundity rates after hormonal stimulation (4) .
The aim of this retrospective study of 1131 consecutive IUI-D cycles was to determine the efficacy and to define the important predictors of pregnancy. To achieve this, the clinical pregnancy rate was related to the number of follicles, the time of ovulation, the length of follicular phase, type of hormonal treatment, endometrial development, age of the women and number of inseminated motile sperms. Some of the measures were not accessible for all treatment cycles (Table III) .
Material and methods

Patient selection
All couples admitted to our department and treated with IUI-D for infertility from August 1990 until August 1998 were included. The indications for IUI-D were azoospermia, severe oligozoospermia or inappropriate male genetic disorders. Prior to the treatment all female partners were screened with serum-FSH, -LH, -prolactin and -estradiol on cd 2, and -progesterone on cd 21. Tubal patency was evaluated either by hysterosalpingography or laparoscopy.
Generally the couples were offered six treatment cycles with at least one treatment free cycle in between. However, for various reasons, a minor number of couples were offered up to nine treatment cycles.
Standard hormonal stimulation/ovulation induction and cycle monitoring
One hundred mg of Clomiphene Citrate (CC) was administered for 5 days, from cd 3 to cd 7. In addition, 75 IU of FSH or hMG was administered on cd 8 and 9. Follicular and endometrial growth was monitored by transvaginal ultrasonography on cd 10. No further hormonal stimulation was given if the diameter of the leading follicle was 14 mm or more. Presuming a daily follicle growth of 2 mm, 10.000 IU of hCG was given by i.m. injection on the day when a follicular diameter of 17-18 mm could be expected. If the leading follicle on cd 10 was less than 14 mm the hormonal treatment was continued and the patient returned 2-3 days C Acta Obstet Gynecol Scand 80 (2001) later for a repeat ultrasonography. If more than 4 mature follicles were present, the insemination was generally cancelled and in the next cycle, the patient was subsequently stimulated with 100 mg Clomiphene Citrate only from cd 3 to 7. In a minor number of patients, mainly younger women with proven fertility, no hormonal stimulation was given in the first 2 to 3 treatment cycles. If pregnancy had not occurred, standard hormonal stimulation was offered for the remaining cycles. In some cases, due to anovulation or low response in the previous cycle, a more comprehensive hormonal treatment with low dose hMG or ultrashort GnRH downregulation and hMG stimulation was used.
Semen preparation
Cryopreserved donor semen from a commercial sperm bank (Cryos Aps, Århus, Denmark) was used throughout the whole period. The semen samples were delivered in straws containing 0.5 ml semen with a guaranteed mean content of 10 million motile sperms after thawing. The frozen straw was allowed to thaw at room temperature and shortly after it was transferred to 0.5 ml IVF-media (Medicult, Copenhagen, Denmark). The concentration, motility and percentage of motile spermatozoa were assessed in a Horwell counting chamber (Hawksley & Son, Lancing, UK). The semen specimen was layered on a 40/80% Percoll gradient (Pharmacia, Uppsala, Sweden) and centrifuged for 25 minutes at 300 g at room temperature. The supernatant was then removed and the pellet was resuspended twice in 2.5 ml IVF-media and centrifuged at 300 g for 10 minutes. The pellet was resuspended in 0.5 ml IVF-media. Concentration, motility and total number of motile spermatozoa were determined. If the total number of motile sperms were less than 2 million, another straw was thawed and prepared in the same manner. The suspension was left at 37aeC in incubator for less than 10 minutes until insemination.
Insemination
A transvaginal ultrasonography was performed prior to insemination for evaluation of the number of mature follicles (Ͼ16 mm) and for determination of ovulation (occurrence of collapsed or blood-filled follicles). A single intrauterine insemination was performed 38 hours after hCG administration using a Wallace insemination catheter (H.G. Wallace LTD, Colchester, Essex, UK). The catheter was passed through the cervical canal and the suspension (0.5 ml) was slowly injected into the uterine cavity, after which the catheter was slowly withdrawn. The women did not rest after the insemination and no luteal support was given.
Pregnancy test
In all cases, a blood sample for quantitative betahCG measurement was taken 14 days after insemination irrespective of the occurrence of menstruation. If positive, a transvaginal ultrasonography was performed 32 to 40 days after insemination. The outcome was recorded as clinical pregnancies per cycle and births per cycle. Biochemical (no visible gestational sac at ultrasonography) and ectopic pregnancies were noted, but excluded from the material. All pregnancies were completed before analysis.
Statistical analysis
Statistical analysis was performed using Fisher's exact test. Results were considered significant at pϽ0.05. Odds ratios were calculated to evaluate the impact of the different variables contributing to the success of the IUI-D treatment using Medcalc (Medcalc Software, Mariakerke, Belgium).
Results
A total of 1131 IUI-D cycles in 351 women resulted in 252 clinical pregnancies (Table I ). The number of treatment cycles per couple varied from 1 to 9 with a mean of 3.7 per couple. The overall clinical pregnancy rate per cycle was 22.3%. The rate increased from 12.9% in 1991 to 34.6% in 1998 (Table I ). The cumulative birth rate was 58.7% after 6 attempts and increased to 61.0% only after more than 6 attempts, thus the treatment was successful for almost two thirds of the couples (61%).
The pregnancy rate increased significantly (pϽ0.01) (Table II) if more than one preovulatory follicle (±17 mm on the day of hCG) developed. The percentage triplets and quadruplets was 2.8% on occurrence of 3 follicles but increased markedly (10.3%) on the occurrence of 4 or more follicles. The presence of 2-3 preovulatory follicles gave the best result of treatment in relation to the risk of multiple pregnancies. The mean number of follicles when pregnancy occurred was 2.3 in contrast to 2.1 when pregnancy did not occur. In about one third of the treatment cycles (30.2%) only 1 mature follicle developed. The pregnancy rates according to the different outcome measures are summarized in Table III . A significant difference in the clinical pregnancy rate was seen when ovulation had occurred at the time of insemination (occurrence of a collapsed or blood-filled follicle), being 18.7% without ovulation versus 25.9% with ovulation (pϽ0.01).
Neither the thickness nor the echogenic pattern of the endometrium on cd 10 was significantly correlated to the outcome of the treatment. The pregnancy rate is 26.8% for hypodense, 19.4% for isodense and 16.7% for hyperdense echogenic pattern. If the thickness of the endometrium was less than 6 mm on cd 10 the pregnancy rate was 21.7% versus 30.0% if the endometrium was thicker than 6 mm.
Insemination between cd 13 and 16 resulted in a clinical pregnancy rate of 27.3% compared to 14.5% if insemination was carried out before cd 13. This difference was significant (pϽ0.01). A decreased although not significant rate was found with insemination after cd 16 (18.8%).
CC/hMG-FSH was used for ovarian stimulation in 787 cycles. CC only was used in 126 cycles, in most cases due to a high response in former cycles. In 46 cycles a more comprehensive stimulation regime with low-dose hMG and in 21 cycles GnRH downregulation and FSH/hMG stimulation were used, either due to anovulation or a former low response. In 151 cycles no stimulation was used at all. In this group the clinical pregnancy rate was lower than in the treated groups (16.6% vs. 23.5%), although the difference was not significant. No difference in outcome was found between the other types of treatment.
The clinical pregnancy rate decreased with increasing age of the female, being significantly lower in the age group 35-39 years compared to the age groups under 30 years (pϽ0.01).
Logistic regression analysis revealed five predictive variables for the outcome of intrauterine insemination with donor semen in terms of clinical pregnancy rate (Table IV) . These variables were the number of treatment cycles, the number of mature follicles, the cycle day for insemination, the occurrence of ovulation at the time for insemination and the age of the female.
Discussion
In this retrospective analysis of 1131 IUI-D cycles in 351 couples the overall clinical pregnancy rate was 22.3% and the birth rate 18.9% per insemination. These results are in agreement with other studies finding clinical pregnancy rates ranging (6) . The clinical pregnancy rate rose from 12.9 % in 1991 to 34.6% in 1998. To some extent this reflects a learning curve, but it can be the expression of alterations in patients characteristics, especially a decline in mean female age. In our attempt to define prognostic factors for the outcome of IUI-D, we identified five significant variables: the number of treatment cycles, the number of mature follicles, the length of the follicular phase, the occurrence of ovulation and the age of the female. In the present study the birth rate per cycle was significantly higher in the first treatment cycle (26.5%) and slowly declining from the second cycle (18.8%) and onward (8.5%). The cumulated birth rate increased up to the sixth treatment cycle (58.7) favoring a maximum of six IUI-D cycles before other treatment modalities as IVF or cessation of treatment are considered. This is in agreement with most other studies (2, 4, 7, 8) . However, others have reported of relatively constant rates for the first four to seven cycles (9-11).
The pregnancy rate was significantly lower (16.7%) in the presence of only one preovulatory follicle indicating the necessity of using ovarian stimulation in combination with IUI-D. Similar re-C Acta Obstet Gynecol Scand 80 (2001) sults are found in other studies (6, 7, 12) . However, no significant difference in pregnancy rates was noticed between the presence of two to five mature follicles, allthough the overall multiple pregnancy rate was 24.2%, including 4.4% triplets, being somewhat higher than in other studies (4, 13) . The percentage of triplets was 10% when more than 3 preovulatory follicles were present, compared to 3.6% in presence of less than four follicles. No correlation, however, was found between the number of mature follicles and twin pregnancies. This is in agreement with the results of Goldfarb et al. (13), who found a correlation between the percentage of multiple pregnancies and the total number of follicles, but no correlation to the number of mature follicles. In the study of Navot et al. (14) There was no significant difference in cycle fecundity between the different stimulation regimes in our study, although the clinical pregnancy rate was 16.6% without stimulation, 23% if CC was used and 23.5% after the use of CC/hMG-FSH. This is in contrast to other studies. Depypere et al. (7) found a pregnancy rate of 12.5% in unstimulated, 13.1% in CC and 23.9% in CC/hMG stimulated cycles. This difference is most likely caused by the selection for stimulation in our study, where the milder stimulations were used for women, who already had children born after earlier IUI-D treatment or who had responded with multiple follicular development after CC/hMG-FSH treatment in a previous cycle. Thus in our study, the milder stimulation regimes were presumably used for a more fertile group of women, thereby skewing the results.
A short follicular phase has been correlated to a decreased pregnancy rate in studies by Stanger and Yovich (15) and Check et al. (16) . We made the same observations in our study finding a pregnancy rate of 14.5% when insemination occurred earlier than cd 13, a pregnancy rate of 27.3% if insemination was carried out between cd 13 and 16 (pϽ0.05) and a pregnancy rate of 18.8% if the insemination was later than cd 16 (NS). It seems plausible, although not proven, that either a later start of the hormonal stimulation or a milder stimulation could postpone the time for insemination and thereby increase the pregnancy rate. Similarly, starting hormonal treatment earlier or more intensely could accelerate the time for insemination.
We performed a single insemination 38 hours after the hCG injection at which time ovulation had occurred in 49.9% of the cycles and intact unruptured follicles were seen by ultrasonography in the remainder. The pregnancy rate was 25.9% compared to 18.7% in cycles without ovulation. This difference was significant (pϽ0.01).
To our knowledge no other studies have related the outcome to whether or not ovulation had occurred at the time of insemination. In most studies a fixed time-interval between hCG and insemination ranging from 28 to 40 hours is used without significant difference in pregnancy rates (4, (17) (18) (19) .
The results using double insemination versus single insemination are conflicting. In a prospective randomized study Silverberg et al. (20) compared a single insemination 34 hours after hCG administration with a double insemination 18 and 42 hours after hCG. The pregnancy rate after the double insemination was 50% compared to only 8% after a single insemination. However, in that study there appeared to be a difference in the mean number of mature follicles between the cycles with dual insemination (2.5 follicles) and the cycles with single insemination (1.9 follicles). Other studies such as Ransom et al. (23) could not demonstrate a significant difference between the outcome of a single versus double inseminations. Our findings of a higher pregnancy rate after ovulation seem to indicate that early insemination is not appropriate and dual insemination should only be considered if ovulation has not occurred at the time of insemination. It is unresolved if a prolongation of the time interval from hCG administration to insemination beyond 38 hours would improve the results.
The number of motile spermatozoa used for insemination were not predictive of IUI-D outcome as long as at least 2 million motile spermatozoa were used. This is in agreement with the results published by Pittrof et al. (6) In our study the clinical pregnancy rate was 27.1% in women younger than 30 years and significantly lower, 17.1%, in women aged 35 to 39. This age-related decline in female fecundity has been well documented in other studies by Kang and Wu (9) and Pittrof et al. (6) . At least up to the age of 40, IUI-D results in acceptable pregnancy rates.
Measuring the endometrial diameter and echogenicity sonographically on cd 10 was not predictive for the outcome of IUI-D. A slight but nonsignificant improvement was seen in presence of a trilaminar endometrium exceeding 6 mm. This is in contrast to the studies of Hock et al. (24) , Chang et al. (25) and Dickey et al. (26) , who found C Acta Obstet Gynecol Scand 80 (2001) that the sonographic pattern of the endometrium measured on the day of hCG was predictive for the treatment outcome.
In conclusion, IUI-D is a simple, inexpensive and efficient treatment of azoospermia and severe oligozoospermia resulting in an overall clinical pregnancy rate of 22.3% and a birth rate of 18.9% per treatment cycle. The multiple birth rate was 20.6%.
The best results with an acceptable multiple birth rate were seen in the first treatment cycle in the presence of 2-3 mature follicles, indicating the necessity of hormonal ovarian stimulation, assuming that insemination was performed after cd 12, with more than two million motile spermatozoa after ovulation had occurred. The cumulative birth rate after 6 treatment cycles was 58.7%.
